Respiratory syncytial virus infection

Antiviral antibodies Preventing respiratory syncytial virus infections in premature infants Synagis... [Pg.96]

Donelly, B. 1. (1996). Vitamin A and respiratory syncytial virus infection. Arch. Pediatr. Adolesc. Med. 150, 882-892. [Pg.212]

Ribavirin can inhibit the replication of both RNA and DNA viruses. It is a nucleoside analog which blocks guanosine monophosphate by inhibiting the enzyme inosine monodehydrogenase. Its main indication is severe respiratory syncytial virus infections in infants but it has also shown activity against influenza A and influenza B infections. It is administered by aerosol spray. No serious adverse effects occur when used as aerosol. [Pg.419]

H.A. Haeberle, F. Nesti, H.J. Dieterich, Z. Gatalica, R.P. Garofalo, Perflubron reduces lung inflammation in respiratory syncytial virus infection by inhibiting chemokine expression and nuclear factor-kappaB activation, Am. J. Respir. Crit. Care Med. 165 (2002) 1433-1438. [Pg.483]

Sudden infant death syndrome. Water-soluble smoke extract, in cell culture supernatants of mouse fibroblasts (L-929 cell line), produced an increase in TNF-a from respiratory syncytial virus-infected cells. It decreased TNF-a from cells incubated with toxic shock syndrome toxin. Incubation with cigarette smoke extract decreased the NO production from respiratory syncytial virus-infected cells and increased the NO production from cells incubated with toxic shock syndrome toxin. Monocytes from a minority of individuals demonstrated extreme TNF-a responses and/or very high or very low NO. The proportion of samples in which extreme responses with a very high TNF-a and very low NO were detected was increased in the presence of the three agents to 20% compared with 0% observed with toxic shock syndrome toxin. One to 4% was observed with cigarette smoke extract or respiratory syncytial virus L Symphatomimetic activity. Water extract of the dried leaf, administered intravenously to cats at doses of 0.05 and 10-20 mg/kg. [Pg.333]

Tempest, P.R., Bremner, P., Lambert, M., et al. (1991). Reshaping a human monoclonal-antibody to inhibit human respiratory syncytial virus-infection in vivo. Bio-Technol., 9, 266-271. [Pg.145]

Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev. 2000 13 371-384. [Pg.542]

Ventre K, Randolph A. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev. 2004 CD000181. [Pg.544]

Palivizumab is a monoclonal antibody that binds to the fusion protein of respiratory syncytial virus, preventing infection in susceptible cells in the airways. Its use in neonates at risk for respiratory syncytial virus infection reduces the frequency of infection and hospitalization by about 50% (see Chapter 49 Antiviral Agents). [Pg.1348]

Rumar, M., Behera, A. R., Matsuse, H., Lockey, R. F. and Mohapatra, S. S. (1999). Intranasal IFN-gamma gene transfer protects BALB/c mice against respiratory syncytial virus infection. Vaccine 18, 558-567. [Pg.98]

C. It is currently used to treat severe herpesvirus and respiratory syncytial virus infections as well as AIDS. [Pg.383]

Synagis Medimmune RSV F protein Respiratory syncytial virus infection... [Pg.689]

Bastein, N.,Trudel, M., and Simard, C. (1999), Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines, Vaccine, 17, 832-836. [Pg.650]

Martinez I, Lombardia L, Garcia-Barreno B et aL Distinct gene subsets are induced at different time points after human respiratory syncytial virus infection of A549 cells. J Gen Virol 2007 88(Pi 2) 570-581. [Pg.135]

Rodriguez WJ, Bui RH, Connor JD, Kim HW, Brandt CD, Parrott RH, Burch B, Mace J. Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections. Antimicrob Agents Chemother 1987 31(7) 1143-6. [Pg.31]

Palivizumab Prevention ot respiratory syncytial virus infection Rituximab Chemotherapy-resistant advanced tollicular... [Pg.2381]

In 565 patients with respiratory syncytial virus infections palivizumab caused injection site reactions (2.3%), fever (1.5%), and nervousness/irritability (under 1%) no other adverse effects were reported (4). [Pg.2669]

Groothuis JR. Safety of palivizumab in preterm infants 29 to 32 weeks gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection. Eur J Clin Microbiol Infect Dis 2003 22(7) 414-17. [Pg.2669]

Smith DW, Frankel LR, Mathers LH, Tang AT, Ariagno RL, Prober CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991 325(l) 24-9. [Pg.3039]

Waris ME, Tsou C, Erdman DD, Zaki SR,Anderson LJ. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. / Virol. 1996 70(5) 2852-2860. [Pg.368]

Opensahw PJ, Tregoning JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev. 2005 18(3) 541-555. [Pg.406]

Byrd LG, Prince GA. Animal models of respiratory syncytial virus infection. Clin Infect Dis. 1997 25 1363-1368. [Pg.406]

TNFa is classically associated with septic shock and diverse infectious pathological conditions. It is involved in the development of a protective immune response in tuberculosis. Measurable serum TNFa levels have been detected in 10.5% of children with pulmonary tuberculosis, all of whom belonged to the group with active disease. Results suggest a protective role for TNFa in respiratory syncytial virus infection. In patients with chronic hepatitis C during treatment with IFNa, elevated production of TNFa by PBMCs may be due to host response to the virus. In HIV infection, TNFs and IL-6 stimulate viral replication. [Pg.707]

Neuzil KM, Tang YW, Graham BS. Protective Role.of TNF-a in respiratory syncytial virus infection in vitro and in vivo. Am J Med Sci 1996 311 201-4. [Pg.737]

Rodriguez WJ. Management strategies for respiratory syncytial virus infections in infants. J Pediatr 1999 135(suppl 2) S45-50. [Pg.1961]

Ottolini MG, Hemming VG. Prevention and treatment recommendations for respiratory syncytial virus infection. Drugs 1997 54 867-884. [Pg.1961]

McCarthy CA, Hall CB. Recent approaches to the management and prevention of respiratory syncytial virus infection. Curr Clin Top Infect Dis 1998 18 1-18. [Pg.1961]

Englund JA, Piedra PA, Ahn YM, et al. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr 1994 125 635-641. [Pg.1961]

Committee on Infectious Diseases. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 1996 97 137-140. [Pg.1961]

RUSSI, J.C., DELFRARO, A., BORTHAGARAY, M.D., VELAZQUEZ, B GARCIA-BARRENO, B. HORTAL, M. (1993) Evaluation of immunoglobulin E-specific antibodies and viral antigens in nasopharyngeal secretions of children with respiratory syncytial virus infections. Journal of Clinical Microbiology, 31, 819-823. [Pg.26]

Immunohistochemistry has also been used to confirm the diagnosis of respiratory viral diseases such as influenza A virus and respiratory syncytial virus infections (Fig. 3.12) when cultures were not available. " ... [Pg.64]

Bonfanti J-F, Roymans D (2009) Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Dev 12 479 -87... [Pg.190]

Olszewska W, Openshaw P (2009) Emerging dmgs for respiratory syncytial virus infection. Exp Opin Emerg Drugs 14 207-217... [Pg.191]

Washbume JF, Bocchini JA Jr, Jamison RM (1992) Summertime respiratory syncytial virus infection epidemiology and clinical manifestations. South Med J 85 579-583... [Pg.191]

Halstead DC, Jenkins SG (1998) Continuous non-seasonal epidemic of respiratory syncytial virus infection in the southeast United States. South Med J 91 433 136... [Pg.191]

Simoes EAF (1997) Respiratory syncytial virus infection pathogenesis, treatment and prevention. Curr Opin Infect Dis 10 213-220... [Pg.191]

Walsh EE, Peterson DR, Falsey AR (2004) Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 189 233-238... [Pg.192]

Falsey AR, Hennessey PA, Formica MA et al (2005) Respiratory syncytial virus infection in elderly and high-risk adults. New Engl J Med 352 1749-1759... [Pg.192]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...